Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + SGLT2 inhibitor + GLP-1 receptor agonist for type 2 diabetes remission
ChiCTR2400091159Phase 4Not yet recruiting
- Sponsor
- Dongying People's Hospital
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of metformin, dapagliflozin, empagliflozin, canagliflozin, sotagliflozin and 5 more in type 2 diabetes mellitus (T2DM), sponsored by Dongying People's Hospital. Primary endpoint: glycated hemoglobin (HbA1c). Planned start Oct 2024; status: not yet recruiting.
02
Drugs
metformindapagliflozinempagliflozincanagliflozinsotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400091159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091159.